Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review

Type 1 interferons, especially interferon-beta, has been reported to be effective in COVID-19 patients in multiple randomized controlled trials. The aim of our meta-analysis and systematic review is to assess efficacy of subcutaneous IFN-beta in regards to mortality and discharge rate. Prospective,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abuzar A. Asif, Habiba Hussain, Sriviji Senthil Kumaran, Salman B. Syed, Varun Vanka, Manisha Tharoor, Umme Salma Rangwala, Urvashi Rathore, Malay Singhal, Tulika Chatterjee
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	interferon-beta covid-19 coronavirus meta-analysis systematic review pandemic efficacy subcutaneous Internal medicine RC31-1245
Acceso en línea:	https://doaj.org/article/543ed69dc9d34b20a702f2a6015eb96c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:543ed69dc9d34b20a702f2a6015eb96c
record_format	dspace
spelling	oai:doaj.org-article:543ed69dc9d34b20a702f2a6015eb96c2021-11-17T14:21:57ZEfficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review2000-966610.1080/20009666.2021.1984644https://doaj.org/article/543ed69dc9d34b20a702f2a6015eb96c2021-11-01T00:00:00Zhttp://dx.doi.org/10.1080/20009666.2021.1984644https://doaj.org/toc/2000-9666Type 1 interferons, especially interferon-beta, has been reported to be effective in COVID-19 patients in multiple randomized controlled trials. The aim of our meta-analysis and systematic review is to assess efficacy of subcutaneous IFN-beta in regards to mortality and discharge rate. Prospective, retrospective and randomized controlled trials were included. Primary outcomes measured were 28-day mortality and discharge rate. Secondary outcomes measured were mean hospital stay and post-intervention intubation rate. A thorough literature search was conducted in Medline, PubMed, Ovid journals, Google Scholar, and Cochrane Central Register of Controlled Trials & Database of Systematic Reviews from 1 April 2020 to 28 February 2021. Relative risk was calculated using both the Mantel–Haenszel method (fixed-effects model) and DerSimonian Laird method (random effects model). The heterogeneity among studies was tested using Cochran’s Q test, based upon inverse variance weights. 7 studies were included in the meta-analysis and systematic review. The IFN-beta group did not improve the 28-day mortality (RR = 1.276; 95% CI: 1.106–1.472, p = 0.001) or the discharge rate (RR = 0.906; 95% CI = 0.85–0.95, p = < 0.001). The mean hospital stay was 11.95± 2.5 days in the interferon-beta group and 11.43 ± 3.74 days in the traditional treatment group. Likewise, interferon-beta did not add any advantage to post-intervention intubation rate (RR = 0.92; 95% CI = 0.7841–1.0816, p = 0.3154). Our findings revealed that use of subcutaneous interferon-beta is futile in COVID-19.Abuzar A. AsifHabiba HussainSriviji Senthil KumaranSalman B. SyedVarun VankaManisha TharoorUmme Salma RangwalaUrvashi RathoreMalay SinghalTulika ChatterjeeTaylor & Francis Grouparticleinterferon-betacovid-19coronavirusmeta-analysissystematic reviewpandemicefficacysubcutaneousInternal medicineRC31-1245ENJournal of Community Hospital Internal Medicine Perspectives, Vol 11, Iss 6, Pp 760-768 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	interferon-beta covid-19 coronavirus meta-analysis systematic review pandemic efficacy subcutaneous Internal medicine RC31-1245
spellingShingle	interferon-beta covid-19 coronavirus meta-analysis systematic review pandemic efficacy subcutaneous Internal medicine RC31-1245 Abuzar A. Asif Habiba Hussain Sriviji Senthil Kumaran Salman B. Syed Varun Vanka Manisha Tharoor Umme Salma Rangwala Urvashi Rathore Malay Singhal Tulika Chatterjee Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
description	Type 1 interferons, especially interferon-beta, has been reported to be effective in COVID-19 patients in multiple randomized controlled trials. The aim of our meta-analysis and systematic review is to assess efficacy of subcutaneous IFN-beta in regards to mortality and discharge rate. Prospective, retrospective and randomized controlled trials were included. Primary outcomes measured were 28-day mortality and discharge rate. Secondary outcomes measured were mean hospital stay and post-intervention intubation rate. A thorough literature search was conducted in Medline, PubMed, Ovid journals, Google Scholar, and Cochrane Central Register of Controlled Trials & Database of Systematic Reviews from 1 April 2020 to 28 February 2021. Relative risk was calculated using both the Mantel–Haenszel method (fixed-effects model) and DerSimonian Laird method (random effects model). The heterogeneity among studies was tested using Cochran’s Q test, based upon inverse variance weights. 7 studies were included in the meta-analysis and systematic review. The IFN-beta group did not improve the 28-day mortality (RR = 1.276; 95% CI: 1.106–1.472, p = 0.001) or the discharge rate (RR = 0.906; 95% CI = 0.85–0.95, p = < 0.001). The mean hospital stay was 11.95± 2.5 days in the interferon-beta group and 11.43 ± 3.74 days in the traditional treatment group. Likewise, interferon-beta did not add any advantage to post-intervention intubation rate (RR = 0.92; 95% CI = 0.7841–1.0816, p = 0.3154). Our findings revealed that use of subcutaneous interferon-beta is futile in COVID-19.
format	article
author	Abuzar A. Asif Habiba Hussain Sriviji Senthil Kumaran Salman B. Syed Varun Vanka Manisha Tharoor Umme Salma Rangwala Urvashi Rathore Malay Singhal Tulika Chatterjee
author_facet	Abuzar A. Asif Habiba Hussain Sriviji Senthil Kumaran Salman B. Syed Varun Vanka Manisha Tharoor Umme Salma Rangwala Urvashi Rathore Malay Singhal Tulika Chatterjee
author_sort	Abuzar A. Asif
title	Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title_short	Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title_full	Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title_fullStr	Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title_full_unstemmed	Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
title_sort	efficacy of subcutaneous interferon-beta in covid-19: a meta-analysis and systematic review
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/543ed69dc9d34b20a702f2a6015eb96c
work_keys_str_mv	AT abuzaraasif efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT habibahussain efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT srivijisenthilkumaran efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT salmanbsyed efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT varunvanka efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT manishatharoor efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT ummesalmarangwala efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT urvashirathore efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT malaysinghal efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview AT tulikachatterjee efficacyofsubcutaneousinterferonbetaincovid19ametaanalysisandsystematicreview
_version_	1718425480432975872

Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review

Ejemplares similares